5(top 3%)
Impact Factor
5.5(top 3%)
extended IF
108(top 3%)
H-Index
958
authors
2.2K
papers
64.5K
citations
3.6K
citing journals
27.6K
citing authors

Most Cited Articles of Journal of Immunotherapy

TitleYearCitations
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy2013758
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma2010728
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis2007564
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients2003510
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer2013393
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b2010351
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells2006341
Induction of cytokine production from human monocytes stimulated with alginate1991314
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma2001304
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma2002297
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer2005285
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors2015270
Vitiligo in Patients with Melanoma1996260
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor2009255
Cancer and inflammation: promise for biologic therapy2010254
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma2005252
Human immune response to monoclonal antibodies1994243
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy2009235
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine2011232
A clinical development paradigm for cancer vaccines and related biologics2007225
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma2006222
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients2009219
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity2011214
Tumor-induced immune dysfunctions caused by myeloid suppressor cells2001214
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens2005211